Published in World J Gastroenterol on March 21, 2017
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (2013) 12.44
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med (2016) 8.14
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology (2013) 4.58
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol (2013) 3.13
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ (2015) 2.83
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol (2012) 2.76
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ (2015) 2.54
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke (2013) 2.52
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos (2007) 2.47
Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos (2008) 2.45
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace (2015) 2.35
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost (2015) 2.19
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18
Dabigatran and postmarketing reports of bleeding. N Engl J Med (2013) 2.15
Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost (2013) 1.83
Dabigatran etexilate: a new oral thrombin inhibitor. Circulation (2011) 1.66
The role of endoscopy in the management of acute non-variceal upper GI bleeding. Gastrointest Endosc (2012) 1.53
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med (2016) 1.51
Factor V Leiden thrombophilia. Genet Med (2011) 1.50
Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation – meta-analysis. Circ J (2014) 1.43
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin (2008) 1.42
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost (2013) 1.15
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J (2014) 1.12
The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood (2014) 1.12
Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc (2015) 1.06
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation (2015) 1.02
Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam Clin Pharmacol (2011) 1.02
Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood (2008) 1.01
Novel anticoagulants: bleeding risk and management strategies. Curr Opin Gastroenterol (2013) 0.98
Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc (2013) 0.94
Non-steroidal anti-inflammatory drug-induced enteropathy. Clin Endosc (2012) 0.93
Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. Thromb Haemost (2015) 0.93
Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis (2004) 0.92
Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study. Gastroenterology (2015) 0.91
Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol (2014) 0.91
Prevalence of the factor V-Leiden mutation in four distinct American ethnic populations. Am J Med Genet (1997) 0.86
Activated prothrombin complex concentrate for the prevention of dabigatran-associated bleeding. Br J Haematol (2014) 0.83
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J (2017) 0.82
Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. Aliment Pharmacol Ther (2015) 0.81
Danger ahead: watch out for indirect comparisons! J Am Coll Cardiol (2012) 0.80
Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. J Thromb Thrombolysis (2015) 0.80
Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials. Dig Liver Dis (2015) 0.80
Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials. Acad Emerg Med (2016) 0.80
Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis. Thromb Res (2015) 0.79
The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa. Ann Hematol (2014) 0.78
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med (2014) 0.77
Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med (2014) 0.77
The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. Br J Clin Pharmacol (2016) 0.77
A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation. J Thromb Thrombolysis (2016) 0.76
Reversal of novel oral anticoagulants. Curr Opin Pharmacol (2016) 0.76
Matching the NOAC to the Patient: Remember the Modifiable Bleeding Risk Factors. J Am Coll Cardiol (2015) 0.76